About This Calculator

This Vectibix (panitumumab) Dosing Calculator provides a recommended dose and infusion plan based on patient weight and the selected FDA-approved dosing regimen. It is designed to assist healthcare professionals in preparing and administering panitumumab for patients with wild-type RAS metastatic colorectal cancer (mCRC). All calculations should be independently verified against the full prescribing information and institutional protocols.

Outputs Explained

The calculator generates a comprehensive infusion plan with the following key outputs:

• Total Panitumumab Dose (mg): The patient-specific dose calculated by multiplying the patient’s weight in kilograms by the selected dose per kilogram (6 mg/kg or 9 mg/kg).
• Volume of Vectibix to Withdraw (mL): The volume of Vectibix (concentration 20 mg/mL) needed to achieve the total calculated dose.
• Recommended Diluent Volume (mL): The volume of 0.9% Sodium Chloride Injection, USP, required for dilution. This is typically 100 mL for doses ≤ 1000 mg and 150 mL for doses > 1000 mg.
• Total Final Infusion Volume (mL): The sum of the Vectibix volume and the diluent volume.
• Recommended Infusion Time (minutes): The standard infusion duration, which is 60 minutes for doses ≤ 1000 mg and 90 minutes for doses > 1000 mg.
• Calculated Infusion Rate (mL/hour): The rate at which the final solution should be infused to meet the recommended time.

How to Use the Tool

To calculate the appropriate dose and infusion parameters, follow these steps:

1. Enter Patient Body Weight: Input the patient’s current weight. The tool accepts values between 20 and 300.
2. Select Weight Units: Choose whether the entered weight is in kilograms (kg) or pounds (lbs). The calculator will automatically convert lbs to kg for the calculation.
3. Choose Dosing Regimen: Select one of the two standard regimens: 6 mg/kg every 14 days or 9 mg/kg every 21 days.

The results will be displayed automatically upon entering a valid weight.

Dosing Overview

Vectibix (panitumumab) is administered as an intravenous infusion. The recommended dose depends on the chosen administration schedule. The two approved monotherapy and combination therapy regimens are:

• 6 mg/kg administered every 14 days as a 60-minute infusion (for doses ≤ 1000 mg) or a 90-minute infusion (for doses > 1000 mg).
• 9 mg/kg administered every 21 days as a 60-minute infusion (for doses ≤ 1000 mg) or a 90-minute infusion (for doses > 1000 mg).

Dose modifications, including reductions, withholding, or discontinuation, may be necessary to manage adverse reactions such as severe dermatologic toxicity or infusion reactions.

Switching Regimens

The decision to switch a patient between the 14-day and 21-day dosing schedule should be made by the treating clinician based on clinical assessment, patient convenience, and specific treatment protocols. There is no specific guidance in the prescribing information for a washout period when switching regimens. The new regimen should commence at the next scheduled dosing cycle.

Missed Dose

If a dose of Vectibix is missed, it should be administered as soon as possible. The schedule for subsequent doses should be adjusted to maintain the correct interval (14 or 21 days) between doses. Consult with the oncology pharmacy and treating physician for specific guidance based on the patient’s treatment plan.

Safety Alerts

Frequently Asked Questions (FAQ)

What is the purpose of this calculator?

This calculator is a clinical support tool for healthcare professionals to determine patient-specific dosing and infusion parameters for Vectibix based on established FDA-approved regimens.

What happens if I enter a weight outside the 20-300 range?

The calculator will display an error message, as dosing for patients outside this weight range has not been characterized in the same way and requires specific clinical judgment.

How does the calculator determine the infusion time and diluent volume?

It follows the guidance in the prescribing information: a total dose of 1000 mg or less is diluted in 100 mL and infused over 60 minutes. A total dose greater than 1000 mg is diluted in 150 mL and infused over 90 minutes.

Can I use this calculator for pediatric patients?

No. The safety and effectiveness of Vectibix in pediatric patients have not been established. This calculator is intended for adult dosing only.

Does the final concentration of panitumumab matter?

Yes. The final concentration of the diluted solution should not exceed 10 mg/mL. The calculator’s recommended diluent volumes adhere to this requirement.

Is this calculator a substitute for professional medical advice?

Absolutely not. This tool is for informational and educational purposes only. It is not a substitute for clinical judgment, institutional protocols, or the official prescribing information, which should always be consulted as the primary reference.

What should I do if the calculated infusion rate seems too high?

The maximum recommended infusion rate is 1000 mL/hour. The calculator’s logic adheres to this limit. If there are any concerns about the rate for a specific patient, consult with a pharmacist or the treating physician.

Does the tool account for dose reductions due to toxicity?

No. This tool calculates the initial, full dose. Any dose adjustments or reductions due to adverse events must be determined by the healthcare provider according to the dose modification guidelines in the prescribing information.

References

1. Vectibix (panitumumab) Full Prescribing Information. U.S. Food and Drug Administration. Revised: June 2021. Accessed on the current date.
2. Vectibix (panitumumab) for Healthcare Professionals. Amgen Inc. Accessed on the current date.
3. Vectibix (panitumumab) European Public Assessment Report (EPAR). European Medicines Agency. Accessed on the current date.
4. Fakih MG. Panitumumab for the treatment of metastatic colorectal cancer. Clin Med Insights Oncol. 2011;5:159-170. doi:10.4137/CMO.S4409. Accessed via PubMed Central.